Participated · Equity · Nov 2021

Moonbird is a Belgian healthtech startup founded in 2019 that offers a palm-sized breathing device paired with an app. The handheld device slows breathing, monitors heart rate, and lets users track progress through short, guided exercises to calm anxiety and fall asleep faster. Founders Stefanie and Michael Broes developed the product after seeing friends and family struggle with insomnia and anxiety. After a successful rollout in Belgium, the company is expanding into other European countries. Moonbird raised €1.5M in a growth round to fund international expansion and scale distribution of its compact, discreet device based on scientifically proven breathing principles.

Participated · Series A · Sep 2015

Ancoa provides contextual surveillance and analytics for exchanges, regulators and buy- and sell-side firms. Its monitoring and surveillance platform delivers real-time monitoring, analytics, alerting, reporting and visualisation tools on a single platform. The product helps firms identify and manage regulatory, reputational and operational risks, including market abuse, fraud and operational shortcomings. The company is led by CEO Kurt Vandebroek and was founded in 2010; it is based in London. Ancoa closed a £4.145m Series A to support growth. The company intends to use the funds to expand internationally, widen its presence and increase the team to 40 staff by 2016.

Participated · Equity · May 2015

Bluebee provides a cloud-based genomics analysis solution combined with accelerated hardware to enable fast and efficient processing of large volumes of genomics data. Its technology aims to reduce complexity and throughput time for research centres, clinical labs and diagnostics companies. The company was founded in 2011 by Prof. dr. ir. Koen Bertels as a spin-off of Delft University of Technology and Imperial College London and is led by CEO Hans Cobben. Bluebee is based in Delft, The Netherlands. It raised €10M in Series A funding and intends to use the proceeds to innovate the Bluebee platform. The financing supports continued product development and scaling of its cloud high-performance genomics solutions. Bluebee provides a cloud-based, distributed computing platform combined with accelerated hardware to process large sequencing data volumes in very short timeframes. The platform has been piloted by Tier 1 clinical research labs such as DKFZ (German Cancer Research Center). Bluebee was founded in 2011 as a spin-off of Delft University of Technology and Imperial College London and is led by CEO Hans Cobben. The company is based in Delft, The Netherlands. It offers a genomics solution aimed at clinicians and labs and intends to expand adoption in those markets. Bluebee raised external funding to support that go-to-market effort.